NCT02253082 - Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions

Aortic Aneurysm, ThoracicEndothelial Dysfunction

Interventions

DRUG

OctaplasLG®

OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.

BIOLOGICAL

Fresh frozen plasma

Standard FFP from the Blood Bank

Trial Locations (1)

DK-2100

Rigshospitalet, Copenhagen University Hospital, Copenhagen